In Depth 10 Mar 2021
Can Gene Therapy Cure Blindness?
Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
Horama
- Latest Posts
Best in Biotech 21 May 2019
The Top 20 Women in Leading Biotech Roles in Europe
The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are…
Interview 25 Sep 2018
How to Overcome Failure as a Biotech Company
Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of…
News and Trends 18 Sep 2018
Update: French Biotech Raises €22M for a Gene Therapy Trial in Retinitis Pigmentosa
Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The…
ADVERTISEMENT
News and Trends 11 Jul 2018
Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time
French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase…
Best in Biotech 27 Dec 2017
The Biggest Biotech News of 2017: What Happened This Year?
Still catching up on news? We've picked out the most exciting things that happened besides clinical results and finance. Here's the biggest biotech news of 2017. We've been recapping the…
News and Trends 11 Oct 2017
French Gene Therapy to Cure Retinitis Pigmentosa Enters the Clinic
Horama has been authorized to start a Phase I/II trial in France testing HORA-PDE6B, a one-off gene therapy with the potential to cure retinitis pigmentosa. Based in Paris, Horama develops…
News and Trends 8 Jul 2016
French Startup raised €4M for Gene Therapy to fix specific Types of Blindness
Horama is developing gene therapies for several hereditary retinal dystrophies. It has now raised €4M in its Series A round, which will speed up development of two candidates. Eye disorders…
